{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:07:22Z","timestamp":1793048842409,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacl.2025.03.013","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T19:55:30Z","timestamp":1742673330000},"page":"382-403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association"],"prefix":"10.1016","volume":"19","author":[{"given":"Fiza","family":"Javed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhimanyu","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5926-7784","authenticated-orcid":false,"given":"Nivedita","family":"Patni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-3666","authenticated-orcid":false,"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7794-1835","authenticated-orcid":false,"given":"Lauren","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7810-4024","authenticated-orcid":false,"given":"Zahid","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.03.013_bib0001","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/17446651.2024.2365787","article-title":"Etiology and emerging treatments for familial chylomicronemia syndrome","volume":"19","author":"Spagnuolo","year":"2024","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jacl.2025.03.013_bib0002","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia\u2014current diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.593931","article-title":"A comprehensive update on the chylomicronemia syndrome","volume":"11","author":"Goldberg","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacl.2025.03.013_bib0004","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/1573403X14666180123165542","article-title":"Hypertriglyceridemia-common causes, prevention and treatment strategies","volume":"14","author":"Rygiel","year":"2018","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.jacl.2025.03.013_bib0005","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects and treatment","volume":"176","author":"Yuan","year":"2007","journal-title":"CMAJ"},{"key":"10.1016\/j.jacl.2025.03.013_bib0006","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1210\/endrev\/bnab037","article-title":"A modern approach to dyslipidemia","volume":"43","author":"Berberich","year":"2022","journal-title":"Endocrine Rev"},{"key":"10.1016\/j.jacl.2025.03.013_bib0007","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/joim.13016","article-title":"Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia","volume":"287","author":"Baass","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2025.03.013_bib0008","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fendo.2020.00455","article-title":"Genetics of hypertriglyceridemia","volume":"11","author":"Dron","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacl.2025.03.013_bib0009","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4158\/EP-2018-0157","article-title":"Familial chylomicronemia syndrome: a clinical guide for endocrinologists","volume":"24","author":"Falko","year":"2018","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jacl.2025.03.013_bib0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/genes16010055","article-title":"Lipoprotein lipase: structure, function, and genetic variation","volume":"16","author":"Perera","year":"2025","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jacl.2025.03.013_bib0011","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jacl.2018.03.093","article-title":"Clinical and biochemical features of different molecular etiologies of familial chylomicronemia","volume":"12","author":"Hegele","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0012","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2796.2012.02516.x","article-title":"Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia","volume":"272","author":"Surendran","year":"2012","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2025.03.013_bib0013","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cmet.2019.05.023","article-title":"GPIHBP1 and lipoprotein lipase, partners in plasma triglyceride metabolism","volume":"30","author":"Young","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.jacl.2025.03.013_bib0014","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MOL.0000000000000680","article-title":"Apolipoprotein C-II: the re-emergence of a forgotten factor","volume":"31","author":"Wolska","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0015","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.bbalip.2011.10.006","article-title":"Lipase maturation factor 1: a lipase chaperone involved in lipid metabolism","volume":"1821","author":"P\u00e9terfy","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jacl.2025.03.013_bib0016","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jacl.2018.05.013","article-title":"Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study","volume":"12","author":"Blom","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0017","article-title":"Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America","author":"Hegele","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0018","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.03.013_bib0019","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/M19-0203","article-title":"The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment","volume":"170","author":"Chait","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2025.03.013_bib0020","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12944-020-01302-x","article-title":"The burden of familial chylomicronemia syndrome in Canadian patients","volume":"19","author":"Gaudet","year":"2020","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2025.03.013_bib0021","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12944-021-01517-6","article-title":"Incidence, predictors and patterns of care of patients with very severe hypertriglyceridemia in Ontario, Canada: a population-based cohort study","volume":"20","author":"Berberich","year":"2021","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2025.03.013_bib0022","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1210\/js.2019-00214","article-title":"Differentiating familial chylomicronemia syndrome from multifactorial severe hypertriglyceridemia by clinical profiles","volume":"3","author":"O'Dea","year":"2019","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.jacl.2025.03.013_bib0023","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacl.2018.10.006","article-title":"Severe hypertriglyceridemia is primarily polygenic","volume":"13","author":"Dron","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0024","doi-asserted-by":"crossref","first-page":"dgae804","DOI":"10.1210\/clinem\/dgae804","article-title":"Dysbetalipoproteinemia: focus on a neglected lipid disorder","author":"Berberich","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2025.03.013_bib0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MED.0000000000000695","article-title":"Advances in the care of lipodystrophies","volume":"29","author":"Shamsudeen","year":"2022","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.jacl.2025.03.013_bib0026","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jacl.2022.08.001","article-title":"GPIHBP1 autoantibody is an independent risk factor for the recurrence of hypertriglyceridemia-induced acute pancreatitis","volume":"16","author":"Zhang","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0027","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jacl.2018.04.009","article-title":"The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study","volume":"12","author":"Davidson","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0028","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2018.12.019","article-title":"Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemia","volume":"283","author":"Paquette","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.03.013_bib0029","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1507\/endocrj.EJ20-0123","article-title":"Gene expression profiles of recurrent acute pancreatitis risk in patients with sustained chylomicronemia","volume":"67","author":"Tremblay","year":"2020","journal-title":"Endocr J"},{"key":"10.1016\/j.jacl.2025.03.013_bib0030","doi-asserted-by":"crossref","first-page":"E1332","DOI":"10.1210\/clinem\/dgaa838","article-title":"10-year comparative follow-up of familial versus multifactorial chylomicronemia syndromes","volume":"106","author":"Belhassen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2025.03.013_bib0031","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.21037\/tp-22-515","article-title":"Familial chylomicronemia syndrome in children: a diagnosis challenge","volume":"11","author":"Ariza","year":"2022","journal-title":"Transl Pediatr"},{"key":"10.1016\/j.jacl.2025.03.013_bib0032","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1161\/ATVBAHA.124.320955","article-title":"Ethnic diversity and distinctive features of familial versus multifactorial chylomicronemia syndrome: insights from the UK FCS National Registry","volume":"44","author":"Bashir","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0033","first-page":"dgae613","article-title":"Comparison of patients with familial chylomicronemia syndrome and multifactorial chylomicronemia syndrome","author":"Spagnuolo","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2025.03.013_bib0034","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S0140-6736(02)11202-5","article-title":"Siblings with hepatosplenomegaly and lipoprotein lipase deficiency","volume":"360","author":"Schneider","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2025.03.013_bib0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.tcm.2019.03.001","article-title":"Familial chylomicronemia syndrome: a rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis","volume":"30","author":"Chyzhyk","year":"2020","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.jacl.2025.03.013_bib0036","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.epsc.2016.12.001","article-title":"The fatty spleen: severe hypertriglyceridemia leading to splenomegaly in a child","volume":"17","author":"Kniery","year":"2017","journal-title":"J Pediatr Surg Case Rep"},{"key":"10.1016\/j.jacl.2025.03.013_bib0037","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025858","article-title":"Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as a marker of cardiovascular risk","volume":"11","author":"Glavinovic","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2025.03.013_bib0038","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jacl.2020.04.011","article-title":"Genetic testing in dyslipidemia: a scientific statement from the National Lipid Association","volume":"14","author":"Brown","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0039","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S2213-8587(19)30264-5","article-title":"Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement","volume":"8","author":"Hegele","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0040","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1194\/jlr.D045963","article-title":"LipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias","volume":"55","author":"Johansen","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2025.03.013_bib0041","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacl.2017.03.015","article-title":"Extreme hypertriglyceridemia, pseudohyponatremia, and pseudoacidosis in a neonate with lipoprotein lipase deficiency due to segmental uniparental disomy","volume":"11","author":"Ashraf","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0042","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jacl.2022.11.007","article-title":"The longitudinal triglyceride phenotype in heterozygotes with LPL pathogenic variants","volume":"17","author":"Perera","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.002","article-title":"Diagnostic algorithm for familial chylomicronemia syndrome","volume":"23","author":"Stroes","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jacl.2025.03.013_bib0044","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \u201cFCS score.\u201d","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.03.013_bib0045","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3111\/13696998.2013.779277","article-title":"Medical resource use and costs associated with chylomicronemia","volume":"16","author":"Gaudet","year":"2013","journal-title":"J Med Econ"},{"key":"10.1016\/j.jacl.2025.03.013_bib0046","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.03.013_bib0047","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.03.013_bib0048","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jacl.2018.04.010","article-title":"Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span","volume":"12","author":"Williams","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0049","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jacl.2015.12.023","article-title":"Editorial commentary: dietary management of familial chylomicronemia syndrome","volume":"10","author":"Williams","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0050","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/nutrit\/nuw002","article-title":"Coconut oil consumption and cardiovascular risk factors in humans","volume":"74","author":"Eyres","year":"2016","journal-title":"Nutr Rev"},{"key":"10.1016\/j.jacl.2025.03.013_bib0051","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ajcn\/36.5.950","article-title":"Medium-chain triglycerides: an update","volume":"36","author":"Bach","year":"1982","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacl.2025.03.013_bib0052","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jacl.2023.05.099","article-title":"Nutrition interventions for adults with dyslipidemia: a clinical perspective from the National Lipid Association","volume":"17","author":"Kirkpatrick","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0053","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1542\/peds.2008-0367","article-title":"Spectrum and management of hypertriglyceridemia among children in clinical practice","volume":"123","author":"Manlhiot","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.jacl.2025.03.013_bib0054","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacl.2018.09.007","article-title":"Extreme hypertriglyceridemia: genetic diversity, pancreatitis, pregnancy, and prevalence","volume":"13","author":"Chyzhyk","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0055","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/ejcn.2016.70","article-title":"Effects of two therapeutic dietary regimens on primary chylomicronemia in paediatric age: a retrospective data analysis","volume":"70","author":"Helk","year":"2016","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.jacl.2025.03.013_bib0056","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5507\/bp.2018.044","article-title":"Therapeutic plasma exchange in secondary prevention of acute pancreatitis in pregnant patient with familial hyperchylomicronemia","volume":"163","author":"Michalova","year":"2019","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1016\/j.jacl.2025.03.013_bib0057","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/01443610801916387","article-title":"Successful pregnancy in Fredrickson type I hyperlipidaemia","volume":"28","author":"Sharma","year":"2008","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0058","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jacl.2023.03.005","article-title":"A novel homozygous nonsense variant of LMF1 in pregnancy-induced hypertriglyceridemia with acute pancreatitis","volume":"17","author":"Tanaka","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0059","doi-asserted-by":"crossref","first-page":"130","DOI":"10.6065\/apem.2346208.104","article-title":"Six-year follow-up of a child with familial chylomicronemia syndrome: disease course and effectiveness of gemfibrozil treatment\u2014case report and literature review","volume":"29","author":"Mustafa","year":"2024","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"10.1016\/j.jacl.2025.03.013_bib0060","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jacl.2016.02.015","article-title":"Identification and characterization of two novel mutations in the LPL gene causing type I hyperlipoproteinemia","volume":"10","author":"Pingitore","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13256-020-02609-0","article-title":"Familial chylomicronemia syndrome: a case report","volume":"15","author":"Susheela","year":"2021","journal-title":"J Med Case Reports"},{"key":"10.1016\/j.jacl.2025.03.013_bib0062","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.numecd.2024.02.006","article-title":"Long-term clinical outcomes and management of hypertriglyceridemia in children with Apo-CII deficiency","volume":"34","author":"Yoldas Celik","year":"2024","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacl.2025.03.013_bib0063","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jacl.2012.11.006","article-title":"Lipoprotein abnormalities in compound heterozygous lipoprotein lipase deficiency after treatment with a low-fat diet and orlistat","volume":"7","author":"Blackett","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0064","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.aace.2021.11.004","article-title":"The use of orlistat in an adult with lipoprotein lipase deficiency: a case report","volume":"8","author":"Jarrett","year":"2021","journal-title":"AACE Clin Case Reports"},{"key":"10.1016\/j.jacl.2025.03.013_bib0065","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1210\/jc.2018-00369","article-title":"Orlistat therapy for children with type 1 hyperlipoproteinemia: a randomized clinical trial","volume":"103","author":"Patni","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2025.03.013_bib0066","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/jamainternmed.2013.13309","article-title":"Severe hypertriglyceridemia with pancreatitis: thirteen years\u2019 treatment with lomitapide","volume":"174","author":"Sacks","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacl.2025.03.013_bib0067","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2022.08.017","article-title":"Efficacy and safety of lomitapide in familial chylomicronaemia syndrome","volume":"359","author":"Cefal\u00f9","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.03.013_bib0068","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s12020-020-02506-y","article-title":"Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome","volume":"71","author":"Cefal\u00f9","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.jacl.2025.03.013_bib0069","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.03.013_bib0070","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/eurheartj\/ehab890","article-title":"Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all?","volume":"43","author":"Hegele","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.03.013_bib0071","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4065\/83.4.470","article-title":"Effects of niacin on glucose control in patients with dyslipidemia","volume":"83","author":"Goldberg","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacl.2025.03.013_bib0072","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1001\/archinternmed.2009.461","article-title":"Concerns about heparin therapy for hypertriglyceridemia","volume":"170","author":"Whayne","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2025.03.013_bib0073","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10545-011-9406-5","article-title":"Deletion of GPIHBP1 causing severe chylomicronemia","volume":"35","author":"Rios","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.jacl.2025.03.013_bib0074","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.785756","article-title":"Insulin treatment of hypertriglyceridemia during pregnancy","volume":"12","author":"Cheng","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jacl.2025.03.013_bib0076","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.atherosclerosis.2018.06.870","article-title":"Disappearance of recurrent pancreatitis after splenectomy in familial chylomicronemia syndrome","volume":"275","author":"Marco-Bened\u00ed","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.03.013_bib0077","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJM199609193351203","article-title":"Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene","volume":"335","author":"Benlian","year":"1996","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jacl.2025.03.013_bib0078","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145800","article-title":"Eruptive xanthoma model reveals endothelial cells internalize and metabolize chylomicrons, leading to extravascular triglyceride accumulation","volume":"131","author":"Cabodevilla","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2025.03.013_bib0079","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/clinchem\/41.1.153","article-title":"Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins","volume":"41","author":"Zilversmit","year":"1995","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2025.03.013_bib0080","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jacc.2018.06.042","article-title":"Familial chylomicronemia syndrome: clinical characteristics and long-term cardiovascular outcomes","volume":"72","author":"Shah","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0081","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jacl.2015.12.023","article-title":"Editorial commentary: dietary management of familial chylomicronemia syndrome","volume":"10","author":"Williams","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0082","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.4158\/ACCR-2018-0168","article-title":"Severe hypertriglyceridemia in pregnancy: a case report and review of the literature","volume":"5","author":"Kleess","year":"2018","journal-title":"AACE Clin Case Rep"},{"key":"10.1016\/j.jacl.2025.03.013_bib0083","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1210\/jc.2012-1250","article-title":"Severe hypertriglyceridemia in pregnancy","volume":"97","author":"Goldberg","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2025.03.013_bib0084","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0009-9120(02)00283-7","article-title":"Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase","volume":"35","author":"Al-Shali","year":"2002","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jacl.2025.03.013_bib0085","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12884-020-02965-1","article-title":"Management of a pregnant patient with chylomicronemia from a novel mutation in GPIHBP1: a case report","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.jacl.2025.03.013_bib0086","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/jca.21453","article-title":"Clinical features and treatment of hypertriglyceridemia-induced acute pancreatitis during pregnancy: a retrospective study","volume":"31","author":"Huang","year":"2016","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jacl.2025.03.013_bib0087","first-page":"1837","article-title":"Total parenteral nutrition in a pregnant patient with acute pancreatitis and lipoprotein lipase deficiency (Spanish language article)","volume":"32","author":"Contreras-Bol\u00edvar","year":"2015","journal-title":"Nutr Hosp"},{"key":"10.1016\/j.jacl.2025.03.013_bib0088","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14779072.2017.1372193","article-title":"The burden of familial chylomicronemia syndrome from the patients\u2019 perspective","volume":"15","author":"Gelrud","year":"2017","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jacl.2025.03.013_bib0089","first-page":"447","article-title":"The outcome of a long-term follow-up of pancreatic function after recovery from acute pancreatitis","volume":"7","author":"Symersky","year":"2006","journal-title":"JOP"},{"key":"10.1016\/j.jacl.2025.03.013_bib0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1476-511X-10-157","article-title":"Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study","volume":"10","author":"Sandhu","year":"2011","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2025.03.013_bib0091","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/MCG.0000000000000846","article-title":"Elevated serum triglycerides in the prognostic assessment of acute pancreatitis: a systematic review and meta-analysis of observational studies","volume":"51","author":"Wang","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0092","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1056\/NEJMcp054958","article-title":"Acute pancreatitis","volume":"354","author":"Whitcomb","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.03.013_bib0093","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/MOL.0000000000000866","article-title":"Genetic determinants of pancreatitis: relevance in severe hypertriglyceridemia","volume":"34","author":"Hang","year":"2023","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0094","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/joim.12925","article-title":"Conservative management in hypertriglyceridemia-associated pancreatitis","volume":"286","author":"Berberich","year":"2019","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2025.03.013_bib0095","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.pan.2021.06.002","article-title":"Lactated Ringer's vs normal saline for acute pancreatitis: an updated systematic review and meta-analysis","volume":"21","author":"Aziz","year":"2021","journal-title":"Pancreatology"},{"key":"10.1016\/j.jacl.2025.03.013_bib0096","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1210\/clinem\/dgaa674","article-title":"Lipid management in patients with endocrine disorders: an Endocrine Society Clinical Practice Guideline","volume":"105","author":"Newman","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2025.03.013_bib0097","first-page":"77","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice","volume":"38","author":"Connelly-Smith","year":"2023","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jacl.2025.03.013_bib0098","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1161\/ATVBAHA.120.314168","article-title":"Loss-of-function CREB3L3 variants in patients with severe hypertriglyceridemia","volume":"40","author":"Dron","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2025.03.013_bib0099","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendation","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2025.03.013_bib0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.03.013_bib0101","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425000662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425000662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T03:33:21Z","timestamp":1750649601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425000662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1933287425000662"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.03.013","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}